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Angionvasive mucormycosis is an emerging fungal disease known to affect mainly diabet-
ics  or subjects with profound neutropenia. Infection usually occurs through the inhalation
route, but cutaneous inoculation may occur after trauma or burns. However, mucormyco-
sis  remains unusual in HIV infection. We  report a fatal case of cutaneous mucormycosis
due  to Rhizopus arrhizus involving the scalp following herpes zoster infection. The patient
was  a 42-year-old man with advanced AIDS failing on salvage antiretroviral therapy. The
fungus was diagnosed on the basis of histopathology and culture. Our case emphasizes the
need  to consider mucormycosis in the differential diagnosis of necrotic cutaneous lesionshizopus
IDS
in  patients with late-stage HIV disease.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ntroduction
nvasive fungal infections represent a major cause of
orbimortality in AIDS patients.1 Pneumocystosis, cryp-
ococcosis, and histoplasmosis are typically seen in HIV-
nfected patients with profound immune suppression (e.g.
D4+<200 cells). The rapid expansion of antiretroviral ther-
py has contributed to a reduction in the incidence of
hese fungal infections. However, mucormycosis remains
nfrequently seen in patients whose only risk factor is
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HIV infection, and few cases have been reported in the
literature describing this rare association.2,3 In a recent
systematic review of 929 reported cases of mucormyco-
sis, HIV infection was the attributed risk factor in just
2% but was associated with a higher mortality rate.4 Sim-
ilarly, in a study of 1630 autopsies conducted in AIDS
patients from 1984 to 2002, mucormycosis was detected
in only two cases.5 Herein, we report a fatal case of
cutaneous mucormycosis due to Rhizopus arrhizus in an
AIDS patient failing salvage combination antiretroviral ther-
apy.lsevier Editora Ltda. This is an open access article under the CC
.
i s . 2 0 1 6;2  0(6):637–640
Fig. 2 – Microscopic examination of Rhizopus arrhizus:
unbranched sporangiospores with collapsed columella and638  b r a z j i n f e c t d 
Case  report
A 42-year-old male was admitted to our center with com-
plaints of a severe headache for a month, accompanied by
scalp redness and difﬁculty in making facial movements. His
past medical history included chronic HIV infection, with
poor adherence to antiretroviral drugs. He was diagnosed
with HIV infection in 2008, had been on several antiretrovi-
ral drugs and his latest regimen was a combination of 3TC,
DRV/r, RAL, and MVQ. The most recent immunovirology panel
showed CD4+ T-cell count of 2 cells/mm3 and HIV viral load
of 57.147 copies/mL. One month prior to presentation, he was
seen in the walk-in outpatient clinic for acute sinusitis and
facial herpes zoster; levoﬂoxacin, prednisone, and valacyclovir
were prescribed. The condition deteriorated with the develop-
ment of bilateral facial palsy, diffuse facial edema and multiple
ﬁstulas with purulent discharges over the scalp. Upon admis-
sion, a computed tomography (CT) scan of the brain showed
air ﬂuid levels and mucosal thickening in the left maxillary
and sphenoid sinuses, obliteration of the posterior right eth-
moid cells, and a diffuse increase of the facial subcutaneous
tissue with an organized collection in the left temporal region.
No brain parenchyma lesions were noted.
Broad-spectrum antibiotics were started and blood cul-
tures for mycobacteria, fungi and bacteria were drawn. On
examination, he was underweight (BMI: 15.9 kg/m2) and ane-
mic, but vital signs were normal. Neurological examination
showed bilateral seventh cranial nerve palsy. An area of inﬁl-
trative edema and cellulitis in the scalp and forehead region
was visible coupled with multiple back eschars lesions, some
of them draining serupurulent discharge (Fig. 1). Aspirates of
Fig. 1 – Features on admission: inﬁltrative lesions and
cellulitis concentrated in forehead and scalp region;
multiple ulcers covered with black eschar, draining
seropurulent secretion; seventh nerve palsy.rhizoids. Bar: 100 m.
scalp lesions and a scalp biopsy were performed and sam-
ples were cultured in Sabouraud dextrose Agar 2% (Biolog,
Brazil) and Mycobiotic Agar (Becton, Dickinson and Company,
USA). Cultures were kept at 25 ◦C. Fungal identiﬁcation was
performed by morphophysiological tests, such as macroscopic
and microscopy analysis, and thermo-tolerance. Microscopic
fungal aspects were evaluated under a Zeiss Primo Starlight
microscope. After four days, gray colonies with cotton-like
dense growth were observed. Microscopic aspects of the
fungus included broad-hyphae with a few septa; rhizoids
produced under unbranched sporangiopores that terminated
with dark round sporangia (60–200 m diameter) producing
brown to black sporangiospores (around 6 m length) (Fig. 2).
Histopathology showed a chronic necrotizing and suppurative
granulomatous dermatitis with numerous coenocytic (asep-
tate) hyphae (Fig. 3). The fungus was able to grow at 30 ◦C
and 37 ◦C, but not at 45 ◦C. The fungus was then identiﬁed
as R. arrhizus. Blood cultures taken at hospital admission were
negative.
Initial treatment was intravenous oxacillin and ceftazidime
resulted in partially improvement of the subcutaneous edema
and erythema. Treatment with intravenous deoxycolate
amphotericin B (1 mg/kg/d) was then started on day 7 of
admission. Despite some improvement after amphotericin B
Fig. 3 – Histopathology (hematoxylin–eosin) of scalp
biopsy: chronic necrotizing and suppurative granulomatous
dermatitis with numerous coenocytic (aseptate) hyphae.
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Fig. 4 – Day 10 after admission: persistence of
erythematous lesions dispersed over the scalp region. Note
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that isavuconazole improves treatment success in up to 36% ofhe tiny ulcers covered by black eschars.
dministration, the facial palsy and scalp purulent drainage
emained (Fig. 4). During hospitalization, recurrent episodes
f severe neutropenia were observed and improved by the
ddition of granulocyte colony-stimulant factor. In parallel,
he patient developed several episodes of catheter-associated
epsis due to Pseudomonas aeruginosa,  Methicillin-resistant
taphylococcus aureus,  and ESBL-producing Klebsiella pneu-
oniae. A repeat CT scan after 6-weeks of antibiotic and
ntifungal therapy still showed mucosal thickening and a
mall ﬂuid level in the left maxillary sinus, extensive opaci-
cation of sphenoidal sinus and a small bone discontinuity
f the intersphenoidal sinus. The patient was unsuitable for
inus biopsy due to the ongoing bloodstream infections. After
ight weeks of follow-up, the patient had received a cumu-
ative dose of 2 g of amphotericin B. The patient died on the
9th day of hospital admission and the 41st day of antifungal
herapy.
iscussion
ucormycosis is an emergent fungal infection which
ffects a substantial proportion of immunosuppressed hosts,
specially diabetics, those with hematological malignancy
nd recipients of bone marrow transplants. Fungi are
omprised of two main subphyla – Mucormycotina and
ntomophthoromycotina.6 Disease caused by members of the
ucormycotina play an increasing role in the clinical settings
specially in immunocompromised patients. The usual sites
f infection reﬂect portals of entry and include sinuses, lungs
nd skin.
Cutaneous involvement occurs in almost 20% of cases
nvolving patients without underlying immunosuppression.4
he three main forms are superﬁcial, nodular, and gan-
renous. The mechanism of acquisition is thought to be from
noculation of spores into injured skin. Moreover, hospital-
elated procedures such as catheter insertion, injection sites,
dhesion tapes, wooden tongue depressors, ostomy bags, and
ontaminated cotton clothes are some of the risk factors
reviously described.7 Cases of post-traumatic, such as road6;2 0(6):637–640 639
trafﬁc accidents, scorpion and spider bites, and burns in oth-
erwise healthy individuals have also been reported in the
literature.8–12 The clinical presentation consists of a single,
painful area of cellulitis, which often progress into ecthyma.
Necrosis may develop rapidly and subsequent dissemination
to adjacent tissue may follow. These features are hallmarks of
mucormycosis attributable mainly to angioinvasion and sub-
sequent tissue thrombosis.
Here, we described an AIDS patient with cutaneous
mucormycosis due to R. arrhizus, diagnosed based on a posi-
tive skin histopathology and conﬁrmed by culture. In addition,
we hypothesized that dissemination of the infection to sub-
cutaneous tissue and then to the sinuses (the latter suggested
by the temporal relation and the radiological features in the
absence of the other common causes of sinusitis) did occur.
Even though we could not perform an endoscopic evalu-
ation of the sinuses to make a precise diagnosis, it is likely
that the sinusitis was also due to mucormycosis. In addition,
we argue that the herpetic lesions led to tissue ischemia and
acted as a possible portal of entry and a contributing factor to
the cutaneous mucormycosis superinfection.
HIV-associated mucormycosis does occur predominantly
in relatively young males, with lower CD4+ cell counts but
without the traditional risk factors linked to mucormycosis.13
In some cases, there are underlying predisposing factors
such as transient episodes of neutropenia and intravenous
injections drug abuse. Mucormycosis has been the initial
presentation of HIV infection and, in some cases, unusual
manifestations have been described.14 Co-infection with
other opportunistic diseases such as cytomegalovirus vasculi-
tis, Pneumocystis jirovecii pneumonia, and Kaposi’s sarcoma
resulted in complicated cases as their presence contributes
to increased virulence in the disease process.15 Multi-organ
dissemination does occur.16 Due to the difﬁculty in distin-
guishing mucormycosis from other angioinvasive diseases
(e.g. diseases caused by Aspergillus, Fusarium, Pseudallescheria),
clinicians should always consider mucormycosis in the differ-
ential diagnosis in patients with advanced AIDS. Collectively,
those facts draw attention to the importance of mucormy-
cosis as an emergent severe opportunistic pathogen in the
late-stage of HIV infection.
Mortality rates for mucormycosis vary between 38 and 66%;
however, there is large variation depending on the underlying
condition, site of infection, species involved, and regimen of
antifungals administered.4,17,18 For instance, infection due to
Cunninghamella species, disseminated disease, active malig-
nancy, and monocytopenia were independent predictors of
poor outcome, whereas salvage posaconazole-based therapy
and neutrophil count recovery were predictive of a favorable
outcome.4,17
A combination of surgical debridement coupled with fungi-
cidal therapy improve patient outcomes.6 Amphotericin B
remains the drug of choice. Posaconazole has been used as
a salvage therapy in extensive and refractory cases.6 Recently,
an open-label phase 3 study of isavuconazole – a new broad-
spectrum triazole – for treatment of mucormycosis, showedpatients with primary or refractory disease.19 The main advan-
tages of isavuconazole over other antifungal agents include
the availability of a water-soluble intravenous formulation,
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excellent oral bioavailability, predictable pharmacokinetics,
and fewer side effects.20 Besides administration of antifungal
therapy, it is vital to promptly reverse the underlying risk fac-
tors that triggered mucormycosis (e.g. neutropenia, diabetes
mellitus, corticosteroids). In our case, treatment with gran-
ulocyte colony-stimulating factor was introduced to reverse
neutropenia.
The lipid-based formulations of amphotericin B have
become the antifungals of choice for the treatment of invasive
fungal infections due to less renal toxicity, fewer infusion-
related reactions and provision of higher doses over a shorter
period of time compared to conventional amphotericin B.
We were unable to provide those formulations in our case
because of restricted drug availability due to high drug prices.
However, we  believe that our report represents a real life sit-
uation and mirrors the current challenges facing Brazilian
medical institutions. Provision of the most effective and safe
amphotericin B formulations in the treatment of mucormyco-
sis, especially in the developing world, needs to be urgently
addressed.
Our patient presented severe immunosuppression and
transient episodes of neutropenia occurred prior to and dur-
ing hospitalization, possibly contributing to mucormycosis.
The patient also received high-dose steroid therapy for two
weeks, when herpes zoster and sinusitis were treated before
admission. Despite the extensive sinusitis showed on repeat
CT scans, we  were unable to perform sinus drainage and
debridement because the patient was critically-ill and severely
undernourished, which contraindicated surgery. Prompt sinus
and skin debridement might have allowed a better outcome in
this case.
In conclusion, our case highlights the importance of main-
taining a high index of suspicion for mucormycosis in the
impaired host, especially those at late stage AIDS, presenting
with necrotic cutaneous lesions.
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